3545 results for «2113»
3545 results
Tricuspid valve - How to evaluate?
12 Sep 2025 – From PCR Rio Valves 2025
This session offers a detailed evaluation framework for the tricuspid valve, encompassing clinical decision-making, anatomical assessment with 2D and 3D imaging, quantification of regurgitation, and differentiation of secondary and device-related tricuspid regurgitation, supported by advanced imaging software techniques.
Minimalist approach to tricuspid valve therapy
11 Sep 2025 – From PCR Rio Valves 2025
Discover the minimalist approach to tricuspid valve therapy showcased through TricValve implantation, emphasizing a contrast-free, minimally invasive procedure guided by transthoracic echo and minimal fluoroscopy. Review clinical evidence demonstrating reduced hospitalizations, improved quality of life, and favorable mid-term outcomes such as decreased right heart chamber dimensions...
TAVI outcomes in special clinical settings: cancer, diabetes, and frailty
12 Sep 2025 – From PCR Rio Valves 2025
Delve into the complexities of TAVI outcomes in special clinical populations including patients with cancer, diabetes, and frailty. This session reviews critical analyses and meta-analyses addressing ischemic cerebrovascular events post-TAVI, and compares mortality and post-procedural outcomes between diabetic and non-diabetic patients, providing valuable insights for personalized...
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.
Author
Future directions of drug-coated balloon angioplasty
06 Feb 2025
Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.
Author
Author
